TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

1 - 61 . (canceled)

62 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R is:

wherein each R is substituted or unsubstituted; or

R is

L 1 is a five-membered heterocyclylene, a five-membered heteroarylene, a bond, —CO—, —SO 2 —(CH 2 ) m —, —CH(CH 3 )—, —CH(CF 3 )—, —CF 2 —, —NHC(═O)—, —NHCH 2 —, or

G is:

 wherein

X is —NH(CH 2 ) m CH 3 , —NH(CH 2 ) m -(substituted or unsubstituted Ph), or

Z is CH or N, provided that no more than one Z on any one ring is N;

each Z 1 is independently —CH 2 — or —C(═O)—;

each Z 2 is independently —O—, —S—, or —NH—;

L 2 is a bond, —(CH 2 ) m —, —CO—, —SO 2 —, —(C═O)NH—, or —(C═O)O—;

Y is —H, substituted or unsubstituted C 1-16 alkyl, C 1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH 2 ) m CH 3 , —SO 2 (CH 2 ) 13 CH 3 , or substituted or unsubstituted C 3-10 cycloalkyl;

W is H, hydroxyl, —OCH 3 , —O(CH 2 ) m CH 3 , —NH(C═O)CH 3 , —NH(C═O)(CH 2 ) m CH 3 , —(C═O)—NH(CH 2 ) m CH 3 , substituted or unsubstituted C 1-16 alkyl, C 1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH 2 ) m CH 3 , —N((CH 2 ) m CH 3 ) 2 , —N(CH 3 )(Y), or substituted or unsubstituted C 3-10 cycloalkyl;

each m is independently 1-16;

each n is independently 1-3; and

each p is independently 3-8; or

G is

 wherein

W is hydroxyl, —OCH 3 , —O(CH 2 ) m CH 3 , —NH(C═O)CH 3 , —NH(C═O)(CH 2 ) m CH 3 , unsubstituted C 1-16 alkyl, C 1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH 2 ) m CH 3 , —N((CH 2 ) m CH 3 ) 2 , —N(CH 3 )(Y), or substituted or unsubstituted C 3-10 cycloalkyl;

Y is —H, substituted or unsubstituted C 1-16 alkyl, C 1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH 2 ) m CH 3 , —SO 2 (CH 2 ) 13 CH 3 , or substituted or unsubstituted C 3-10 cycloalkyl; and

each m is independently 1-16;

provided that the compound of Formula (I) is not:

63 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the following formula:

64 . The compound of claim 63 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure of:

(a) Formula (II), wherein L 2 is —(CH 2 ) m —, —SO 2 —, or —CO—;

(b) Formula (III), wherein W is H;

(c) Formula (IV), wherein: W is —OH, —OCH 3 , —O(CH 2 ) m CH 3 , —NH(C═O)CH 3 , or NH(C═O)(CH 2 ) m CH 3 , and each m is independently 4-15;

(d) Formula (V), wherein L 1 is —CO—, —SO 2 —, (—CH 2 —) m or —(CF 2 )—:

(e) Formula (VI), wherein m is 10, 11, or 12; or

(f) Formula (VII), wherein p is 5, 6, 7, or 8; or

(g) Formula (VIII), wherein p is 5, 6, 7, or 8.

65 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein:

R is

66 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein L 1 is a five-membered heteroarylene or a bond.

67 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein L 1 is

wherein Z 3 is N.

68 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein:

G is

69 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein L 1 is a five-membered heterocyclylene, —CO—, —SO 2 —, —(CH 2 ) m —, —CH(CH 3 )—, —CH(CF 3 )—, —CF 2 —, —NHC(═O)—, —NHCH 2 —, or

70 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein G is

71 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein:

R is

L 1 is

 wherein Z 3 is N;

G is

 wherein X is —NH(CH 2 ) m CH 3 ; and

m is 5-10.

72 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein:

R is

L 1 is a bond;

G is

 and

each p is independently 5-8.

73 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein:

G is

 wherein

W is hydroxyl, —OCH 3 , —O(CH 2 ) m CH 3 , —NH(C═O)CH 3 —NH(C═O)(CH 2 ) m CH 3 , unsubstituted C 1-16 alkyl, C 1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH 2 ) m CH 3 , —N((CH 2 ) m CH 3 ) 2 , —N(CH 3 )(Y), or substituted or unsubstituted C 3-10 cycloalkyl;

Y is —H, substituted or unsubstituted C 1-16 alkyl, C 1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH 2 ) m CH 3 , —SO 2 (CH 2 ) 13 CH 3 , or substituted or unsubstituted C 3-10 cycloalkyl; and

each m is independently 1-16.

74 . The compound of claim 62 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) is:

or a pharmaceutically acceptable salt thereof.

75 . A pharmaceutical composition comprising a compound of claim 62 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

76 . The pharmaceutical composition of claim 75 , formulated for oral administration, administration by an injection, enteric delivery, delivery outside of the systemic circulation of a subject, topical or intravesical delivery, or delivery by inhalation.

77 . The pharmaceutical composition of claim 75 , formulated for controlled release within the lower intestine or colon of a subject.

78 . A method for preventing or treating cancer in a subject in need thereof, comprising administering to the subject a compound of claim 69 , or a pharmaceutically acceptable salt thereof.

79 . A method for preventing or treating cancer in a subject in need thereof, comprising administering to the subject a compound of claim 70 , or a pharmaceutically acceptable salt thereof.

80 . A method for preventing or treating a TLR2 protein-mediated disorder selected from an autoimmune disease, a viral infection, and a bacterial infection in a subject in need thereof, comprising administering to the subject a compound of claim 62 , or a pharmaceutically acceptable salt thereof.

81 . A method for modulating the activity of a Toll-like receptor 2 (TLR2) protein or a TLR2-mediated pathway or system in a subject in need thereof, comprising administering to the subject a compound of claim 62 , or a pharmaceutically acceptable salt thereof.